Expert Analysis: ASCO GU 2023

CME

CCO Independent Conference Highlights of the 2023 ASCO Genitourinary Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 28, 2023

Expiration: April 27, 2024

Daniel P. Petrylak
Daniel P. Petrylak, MD
Elizabeth R. Plimack
Elizabeth R. Plimack, MD, MS, FASCO

Activity

Progress
1
Course Completed

Introduction

In this activity, Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS review key studies presented at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare provider, how many patients with genitourinary cancers do you provide care for in a typical month?

The phase III TALAPRO-2 study is evaluating talazoparib plus enzalutamide vs placebo plus enzalutamide in patients with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC). In the primary analysis from TALAPRO-2 presented at ASCO GU 2023, which of the following patient populations experienced radiographic progression-free survival (rPFS) benefit from the addition of talazoparib to enzalutamide?

The phase III ARASENS study evaluated the addition of darolutamide to androgen deprivation therapy (ADT) and docetaxel as a first-line treatment for newly diagnosed hormone-sensitive prostate cancer (HSPC). According to the post hoc analysis results reported at ASCO GU 2023, what is the impact of disease volume and risk on overall survival (OS)?

The phase II TROPHY-U-01 trial examined sacituzumab govitecan in patients with metastatic urothelial carcinoma (mUC). Cohort 2 enrolled patients with progressive disease after immunotherapy and who were ineligible for platinum chemotherapy at the time of enrollment. Which of the following accurately states the outcomes from this cohort that were presented at ASCO GU 2023?

Your patient with advanced renal cell carcinoma (RCC) has progressed on first-line therapy with pembrolizumab plus axitinib. Based on the results of the CaboPoint study examining cabozantinib in patients with progressive disease after previous therapy with immune checkpoint inhibitor (ICI)-based therapy presented at ASCO 2023, what would you tell your patient about the efficacy of cabozantinib as second-line therapy?